Navigation Links
Mesa Labs Reports 8% Increase in Second Quarter Revenues
Date:11/5/2013

quisition related expenses provides the ability to understand the benefits of acquisitions based on their cash return.

We provide non-GAAP adjusted net income and non-GAAP adjusted net income per share amounts in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both non-GAAP and GAAP results.

Our management recognizes that items such as amortization of intangible assets can have a material impact on our net income. To gain a complete picture of all effects on our profit and loss from any and all events, management does (and investors should) rely upon the GAAP statements of income. The non-GAAP numbers focus instead upon our core operating business.

Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

About Mesa Laboratories, Inc.

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins.  We are organized into two divisions across four physical locations.  Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with
'/>"/>

SOURCE Mesa Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 Eli Lilly and Company (NYSE: ... 7 to update the investment community and media on ... conjunction with the 75th American Diabetes Association® Scientific Sessions, ... business, including a review of the Phase III data ... the ADA meeting. The meeting will be ...
(Date:3/30/2015)... ISELIN, N.J. , March 30, 2015 /PRNewswire/ ... a medical device company focused on non-invasive continuous ... it has achieved its wireless mobile communication milestone, ... sensor to transmit data to any mobile platform. ... the strategic transformation of the Company,s technology from ...
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
Breaking Medicine Technology:Lilly Announces Date for Diabetes Investor Meeting 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5
... Colo., March 29, 2011 Encision Inc. (Pink Sheets: ... laparoscopic safety have become intensive topics of discussion in ... Surgery Magazine (March 2011).  The potential complications from laparoscopic ... probably prompted by a recent California case.  The issue ...
... 29, 2011 BioDrain Medical, Inc. (OTC Bulletin ... FDA cleared Streamway™ System for automated surgical fluid ... installation of its patented Streamway™ System in a ... several procedures utilizing the Streamway System and the ...
Cached Medicine Technology:Stray Energy Burns Become a "Hot Topic" in Recent Publications 2Stray Energy Burns Become a "Hot Topic" in Recent Publications 3BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 2BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 3
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio Management ... Forrester Wave™: Strategic Planning For The [Business Technology] BT ... GenSight as a leader and gave the company the ... analytics, corporate strategy, assessment, direction and life cycle support ... Leaders category. , According to the report: GenSight ...
(Date:3/30/2015)... 2015 Follow us on ... are used as tracers to diagnose and treat ... is driven by the increase in the number ... cardiology, neurology, pulmonology, and oncology. Diagnostic radiopharmaceuticals represent ... of radioisotopes in diagnostic imaging. While cardiovascular and ...
(Date:3/30/2015)... El Segundo, CA (PRWEB) March 30, 2015 ... drug tests to accommodate the needs of every industry that ... As employers face compliance mandates or seek new ways to ... is adding new drug panels that will help detect substance ... “Certain industries have mandated drug tests,” said Corra Group Co-Founder, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Cutting-edge doctors ... Health 2015 Conference because of the opportunities to present ... year’s conference will highlight parents of recovered children, who ... Mary Romaniec, will debut her book Victory over Autism: ... Family. Free copies of Victory over Autism will be ...
(Date:3/30/2015)... Bunion Bootie is a great option ... members, friends...and yourself and save. For a limited time only ... 10%, on top of discounts already offered when buying more ... The more Bunion Booties purchased, the more money is saved. ... Bunion Bootie can be worn comfortably and easily in almost ...
Breaking Medicine News(10 mins):Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:Corra Group Adds New Employment Screening Drug Test Solutions for Clients in Every Industry 2Health News:Corra Group Adds New Employment Screening Drug Test Solutions for Clients in Every Industry 3Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2
... release is available in French . , ... support to recruit some of its best minds in ... family foundation has generously pledged $2.5 million to support ... University and the Universit du Qubec,s Institut national de ...
... for suspected pulmonary emboli (PE) is rapidly increasing amongst ... positive studies. This may be due to a failure ... with suspected PE, according to a study performed at ... Rhode Island Hospital, Providence, RI. , Current accepted ...
... Teva Announces First Event in Year of Affordable Healthcare ... consumer health group, recently reported that healthcare premiums in ... between 2000 and 2007. With healthcare costs ... claims being filed, many Americans are finding themselves driven ...
... Records Association (EHR Association) seeks broad stakeholder consensus by ... Act of 2009 (ARRA) as well as specific recommendations ... which will be used to determine eligibility for the ... and hospitals. "I,ve been pleased to have the ...
... M.D., has issued the,following press release: , ... a recent flurry of panic about,the H1N1 (swine influenza). ... cancelled. Some even suggested closing the border with Mexico,where ... back,and forth every day. The panic certainly was ...
... result in quick relief for communities that have been ... Feeding America and The Clorox Company ... communities hit by recent flooding in Eastern Kentucky and ... individuals and families are beginning the arduous task of ...
Cached Medicine News:Health News:Cole Foundation injects $2.5 million to bolster leukemia research 2Health News:ER physicians don't follow clinical guidelines for diagnosing possible pulmonary emboli 2Health News:As Healthcare Costs Skyrocket, Local Leaders Gather to Seek a Solution 2Health News:HIMSS Electronic Health Record Association Reaches Out to Key Stakeholders on 'Meaningful Use' of Certified EHRs 2Health News:HIMSS Electronic Health Record Association Reaches Out to Key Stakeholders on 'Meaningful Use' of Certified EHRs 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Feeding America Partner Support Expedites Disaster Relief and Recovery Efforts 2
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: